AIDS
MCID: HMN044
MIFTS: 75

Human Immunodeficiency Virus Type 1 (AIDS)

Categories: Genetic diseases, Immune diseases

Aliases & Classifications for Human Immunodeficiency Virus Type 1

MalaCards integrated aliases for Human Immunodeficiency Virus Type 1:

Name: Human Immunodeficiency Virus Type 1 58
Aids 58 77 56 17 3
Hiv/aids 58 39 44 3
Human Immunodeficiency Virus Type 1, Susceptibility to 58 30 6
Aids, Delayed/rapid Progression to 58 13
Hiv-1 Viremia, Susceptibility to 58 6
Hiv1 Infection 58 39
Hiv-1 58 39
Rapid Progression to Aids from Hiv1 Infection 58
Human Immunodeficiency Virus I Infection 74
Acquired Immunodeficiency Syndrome 74
Hiv1 Infection, Resistance to 58
Hiv Type 1, Susceptibility to 58
Hiv Infection, Resistance to 58
Hiv/aids, Susceptibility to 58
Aids, Rapid Progression to 58
Aids, Slow Progression to 58
Hiv-1, Susceptibility to 58
Hiv-1, Resistance to 58
Aids, Resistance to 58
Hiv1, Resistance to 58
Hiv-Infection/aids 74
Hiv-1 Infection 17
Hiv-1 Viremia 58
Hiv Type 1 58
Hiv1 58

Classifications:



Summaries for Human Immunodeficiency Virus Type 1

MedlinePlus : 44 HIV stands for human immunodeficiency virus. It harms your immune system by destroying the white blood cells that fight infection. This puts you at risk for serious infections and certain cancers. AIDS stands for acquired immunodeficiency syndrome. It is the final stage of infection with HIV. Not everyone with HIV develops AIDS. HIV most often spreads through unprotected sex with an infected person. It may also spread by sharing drug needles or through contact with the blood of an infected person. Women can give it to their babies during pregnancy or childbirth. The first signs of HIV infection may be swollen glands and flu-like symptoms. These may come and go within two to four weeks. Severe symptoms may not appear until months or years later. A blood test can tell if you have HIV infection. Your health care provider can do the test, or you can use a home testing kit. Or to find free testing sites, call the national referral hotline at 1-800-CDC-INFO (1-800-232-4636 in English and en español; 1-888-232-6348 - TTY). There is no cure, but there are many medicines that fight HIV infection and lower the risk of infecting others. People who get early treatment can live with the disease for a long time. Strategies to reduce the risk of HIV infection include not having sex, limiting your number of sexual partners, never sharing needles, and using condoms the right way every time you have sex. People who are at high risk may take HIV prevention medicines.

MalaCards based summary : Human Immunodeficiency Virus Type 1, also known as aids, is related to aspergillosis and immunodysregulation, polyendocrinopathy, and enteropathy, x-linked, and has symptoms including fever and pruritus. An important gene associated with Human Immunodeficiency Virus Type 1 is CXCL12 (C-X-C Motif Chemokine Ligand 12), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Dolutegravir and Maraviroc have been mentioned in the context of this disorder. Affiliated tissues include t cells, testes and bone, and related phenotypes are hematopoietic system and immune system

OMIM : 58 The pathogenesis of HIV infection and the progression from infection to AIDS vary significantly between exposed individuals. Infection occurs after the virus, which has macrophage (M)- and T lymphocyte (T)-tropic strains and more than 12 subtypes, survives an array of nonspecific, nongenetic environmental and host factors. (609423)

CDC : 3 Help

Wikipedia : 77 Human immunodeficiency virus infection and acquired immune deficiency syndrome (HIV/AIDS) is a spectrum... more...

Related Diseases for Human Immunodeficiency Virus Type 1

Diseases related to Human Immunodeficiency Virus Type 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1931)
# Related Disease Score Top Affiliating Genes
1 aspergillosis 32.7 CD209 IFNG IL10
2 immunodysregulation, polyendocrinopathy, and enteropathy, x-linked 32.4 CCNT1 CCR5 CD209 CD9 CXCL12 IFNG
3 viral infectious disease 32.3 CCL3 CCR5 CD209 IFNG IL10 ITIH4
4 acquired immunodeficiency syndrome 32.0 CCL3 CCR2 CCR5 IFNG IL10 ITIH4
5 encephalitis 31.7 CCL2 CCR5 CD209 ITIH4 TLR3
6 human immunodeficiency virus infectious disease 31.4 BST2 CCL3 CCR2 CCR5 CXCL12 IFNG
7 pneumonia 31.4 CCL11 CCL2 CCL3 IL10
8 meningitis 31.3 CCL2 CCL3 IFNG IL10
9 pulmonary tuberculosis 31.3 CCL3 IFNG IL10
10 measles 31.3 CD209 IFNG TLR3
11 toxoplasmosis 31.2 CCR5 IFNG IL10
12 malaria 31.1 CCL11 CCL2 CCL3 IFNG IL10
13 lymphadenitis 31.1 CD209 IFNG IL10
14 severe acute respiratory syndrome 31.0 CCL2 CD209 IFNG
15 cytomegalovirus retinitis 31.0 CCR2 CCR5 CD9 IFNG
16 bacterial infectious disease 30.9 CCL2 IFNG IL10 TLR3
17 schistosomiasis 30.9 CCL3 IFNG IL10
18 west nile virus 30.9 CCR5 CD209 TLR3
19 sporotrichosis 30.7 IFNG IL10
20 multiple sclerosis 30.6 CCL2 CCL3 CCR5 IFNG IL10
21 mycobacterium tuberculosis 1 30.5 CD209 IFNG IL10
22 bronchiolitis 30.5 CCL11 CCL3 IFNG IL10 IL4R
23 mucocutaneous leishmaniasis 30.5 CCR5 IL10 TLR3
24 asthma 30.5 CCL11 CCL2 CCL3 CXCL12 IFNG IL10
25 hematopoietic stem cell transplantation 30.5 HLA-C IFNG IL10 KIR3DL1
26 interstitial lung disease 30.5 CCL2 IFNG IL10
27 periodontitis 30.4 CCL2 IFNG IL10
28 pulmonary fibrosis, idiopathic 30.4 CCL2 CCL3 CXCL12 CXCR1 IFNG
29 chagas disease 30.4 CCL2 CCL3 CCR5 IFNG IL10
30 variola major 30.4 CCL3 IFNG TLR3
31 trypanosomiasis 30.4 CCL2 CCL3 IFNG IL10
32 polyradiculoneuropathy 30.4 CXCL12 IFNG IL10
33 allergic hypersensitivity disease 30.3 CCL11 IFNG IL10 IL4R
34 mouth disease 30.3 IFNG IL10 TLR3
35 rheumatoid arthritis 30.3 CCL2 CCL3 CCR2 CXCL12 IFNG IL10
36 extrapulmonary tuberculosis 30.3 CCL2 IFNG IL10
37 retinal vasculitis 30.3 CCL2 CX3CR1 TLR3
38 uveitis 30.3 CCL2 IFNG IL10
39 graft-versus-host disease 30.2 HLA-C IFNG IL10
40 pyelonephritis 30.2 CCL2 CXCR1 IL10
41 leptospirosis 30.1 CCL2 IFNG IL10
42 skin disease 30.1 CCL11 HLA-C IFNG IL10
43 dermatitis, atopic 30.1 CCL11 IFNG IL10 IL4R
44 allergic rhinitis 30.1 CCL11 IFNG IL10 IL4R
45 scabies 30.0 CCL11 IL10
46 hemorrhagic fever 30.0 CD209 IFNG IL10
47 demyelinating disease 30.0 CCL2 CCL3 IFNG IL10
48 hand, foot and mouth disease 30.0 IFNG IL10 TLR3
49 fungal meningitis 30.0 CCL2 IFNG IL10
50 spondyloarthropathy 29.9 HLA-C IFNG IL10

Graphical network of the top 20 diseases related to Human Immunodeficiency Virus Type 1:



Diseases related to Human Immunodeficiency Virus Type 1

Symptoms & Phenotypes for Human Immunodeficiency Virus Type 1

Clinical features from OMIM:

609423

UMLS symptoms related to Human Immunodeficiency Virus Type 1:


fever, pruritus

MGI Mouse Phenotypes related to Human Immunodeficiency Virus Type 1:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.06 CCL11 CCR2 CCR5 CD9 CX3CR1 CXCL12
2 immune system MP:0005387 10.03 CCL11 CCL2 CCR2 CCR5 CD9 CX3CR1
3 liver/biliary system MP:0005370 9.7 CCR2 CCR5 CXCL12 IFNG IL10 IL4R
4 neoplasm MP:0002006 9.43 CCR2 CCR5 IFNG IL10 ITIH4 TLR3
5 respiratory system MP:0005388 9.17 CCL11 CCR2 CD9 IFNG IL10 IL4R

Drugs & Therapeutics for Human Immunodeficiency Virus Type 1

Drugs for Human Immunodeficiency Virus Type 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 636)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dolutegravir Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1051375-16-6 54726191
2
Maraviroc Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 376348-65-1 3002977
3
Ritonavir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 155213-67-5 392622
4
Darunavir Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 206361-99-1, 635728-49-3 213039
5
Mycophenolic acid Approved Phase 4,Phase 3,Not Applicable 24280-93-1 446541
6
Zidovudine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 30516-87-1 35370
7
Emtricitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 143491-57-0 60877
8
Efavirenz Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 154598-52-4 64139
9
Lamivudine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 134678-17-4 60825
10
Lopinavir Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 192725-17-0 92727
11
Alendronate Approved Phase 4,Phase 3,Phase 2 66376-36-1, 121268-17-5 2088
12
Calcium Carbonate Approved, Investigational Phase 4,Phase 2 471-34-1
13
Rilpivirine Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 500287-72-9
14
Cobicistat Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1004316-88-4
15
Nelfinavir Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 159989-64-7 64143
16
Stavudine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 3056-17-5 18283
17
Didanosine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 69655-05-6 50599
18
Abacavir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 136470-78-5 441300 65140
19
Amprenavir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 161814-49-9 65016
20
Rifabutin Approved, Investigational Phase 4,Phase 2,Phase 1 72559-06-9 6323490 46783538
21
Nevirapine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 129618-40-2 4463
22
Ribavirin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 36791-04-5 37542
23
Pentoxifylline Approved, Investigational Phase 4 6493-05-6 4740
24
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Not Applicable 93-14-1 3516
25
Methadone Approved Phase 4,Phase 1,Not Applicable 76-99-3 4095
26
Enfuvirtide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 159519-65-0 16130199
27
Peginterferon alfa-2a Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 198153-51-4 5360545
28
Fosamprenavir Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 226700-79-4 131536
29
Indinavir Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 150378-17-9 5362440
30
Rifampicin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 13292-46-1 5381226 5458213
31
Peginterferon alfa-2b Approved Phase 4,Phase 3,Phase 2,Phase 1 99210-65-8, 215647-85-1
32
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 52485-79-7 40400 644073
33
Naloxone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Not Applicable 465-65-6 5284596
34
Tipranavir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 174484-41-4 65027
35
Acyclovir Approved Phase 4,Phase 2,Phase 3,Not Applicable 59277-89-3 2022
36
Etravirine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 269055-15-4 193962
37
Atovaquone Approved Phase 4 95233-18-4 74989
38
Proguanil Approved Phase 4 500-92-5 4923
39
Saquinavir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 127779-20-8 60787
40
tannic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1401-55-4
41
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 94-09-7, 1994-09-7 2337
42
Angiotensin II Approved, Investigational Phase 4,Phase 2,Phase 1 68521-88-0, 11128-99-7, 4474-91-3 172198 65143
43
Losartan Approved Phase 4,Phase 2 114798-26-4 3961
44
Spironolactone Approved Phase 4 52-01-7, 1952-01-7 5833
45
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1 50-28-2 5757
46
Polyestradiol phosphate Approved Phase 4,Phase 2,Phase 1 28014-46-2
47
Atorvastatin Approved Phase 4,Phase 2,Phase 1 134523-00-5 60823
48
Zalcitabine Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 7481-89-2 24066
49
Hydroxyurea Approved Phase 4,Phase 2,Phase 1,Not Applicable 127-07-1 3657
50
Sorbitol Approved Phase 4,Phase 1 50-70-4 5780

Interventional clinical trials:

(show top 50) (show all 2257)
# Name Status NCT ID Phase Drugs
1 A Comparison of Virco®TYPE HIV-1 Testing Versus Expert Interpretation of Genotypic Results for Control of HIV-1 Replication Unknown status NCT00840762 Phase 4
2 Impact of Starting a Dolutegravir-based Regimen on HIV-1 Proviral DNA Reservoir Of Treatment Naïve and Experienced Patients Unknown status NCT02370979 Phase 4
3 Effect of Maraviroc (MCV) on the Immunological Recovery of HIV-1 Discordant Patients With CD4 Lymphocyte Counts Below 200 Cells/mm3 Unknown status NCT01235013 Phase 4 Maraviroc
4 Maraviroc (Celsentri) With Raltegravir and Darunavir/Ritonavir for the Treatment of Triple Class Failure in Adult HIV-1 Infected Patients Unknown status NCT01013987 Phase 4 maraviroc;Raltegravir;Darunavir/ritonavir
5 Efficacy and Safety of Raltegravir (RAL) in Treatment-experienced HIV-1 Infected Adult Chinese Patients Unknown status NCT01201239 Phase 4 raltegravir
6 Effects of Mycophenolate Mofetil (MMF) on Surrogate Markers for Cardiovascular Disease in HIV-1 Infected Patients Unknown status NCT00247494 Phase 4 mycophenol mofetil (MMF, Cellcept®) 500 mg BID
7 Safety and Immune Response to Adjuvanted A(H1N1)v Influenza Vaccine in HIV-1 Infected and Immunosuppressed Adult Patients Unknown status NCT01017172 Phase 4
8 A Pilot Study of Triple NtRTI/NsRTI Therapy in Antiretroviral Naive HIV-1 Infected Patients Unknown status NCT00199121 Phase 4 Zidovudine (drug)
9 Mycophenolate Mofetil in Antiretroviral Naïve Patients 2 (MAN2 Study) Unknown status NCT00120419 Phase 4 mycophenol mofetil (MMF, Cellcept®) 500 mg BID
10 PI Vs. NNRTI Based Therapy for HIV Advanced Disease Unknown status NCT00162643 Phase 4 zidovudine+lamivudine+lopinavir/ritonavir;zidovudine + lamivudine + efavirenz
11 Alendronate for Prevention of AntiRetroviral Therapy-associated Bone Loss Unknown status NCT02322099 Phase 4 Alendronate;Placebo;Tenofovir disoproxil
12 RAL+ATV/r in Comparison With TDF/FTC (or 3TC) +ATV/r in HIV Infected Patients Unknown status NCT01829802 Phase 4 Ritonavir boosted Atazanavir;Raltegravir;TDF/FTC (or 3TC)
13 Open Label, Pilot Study of Darunavir Boosted by Cobicistat in Combination With Rilpivirine to Treat HIV+ Naïve Subjects Unknown status NCT02404233 Phase 4 darunavir/cobicistat;rilpivirine
14 Treatment With Nelfinavir or Efavirenz of HIV-Infected Patients Who Have Never Received Anti-HIV Drugs Unknown status NCT00005000 Phase 4 Nelfinavir mesylate;Efavirenz;Lamivudine;Keyhole-Limpet Hemocyanin;Stavudine;Zidovudine;Didanosine
15 Effectiveness and Safety of Epivir/Ziagen/Zerit (3TC/ABC/d4T) Versus Epivir/Ziagen/Sustiva (3TC/ABC/EFV) Versus Epivir/Ziagen/Agenerase/Norvir (3TC/ABC/APV/RTV) in HIV Patients Who Have Never Received Treatment Unknown status NCT00005017 Phase 4 Ritonavir;Abacavir sulfate;Amprenavir;Efavirenz;Lamivudine;Stavudine
16 Safety and Effectiveness of TRIZIVIR (Abacavir/Lamivudine/Zidovudine) With Efavirenz in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs Unknown status NCT00011895 Phase 4 Abacavir sulfate, Lamivudine and Zidovudine;Efavirenz
17 Protease Inhibitor Monotherapy Versus Ongoing Triple-therapy in the Long Term Management of HIV Infection (PIVOT) Unknown status NCT01230580 Phase 4 Protease Inhibitor;Standard-of-care Antiretroviral therapy
18 SHARE: Simple HAART With Abacavir, Reyataz, and Epivir Unknown status NCT00426296 Phase 4 atazanavir (Reyataz);ritonavir (Norvir)
19 The Dolutegravir Antiretroviral Mono-Therapy for HIV Trial Unknown status NCT02401828 Phase 4 Dolutegravir
20 Raltegravir + Lamivudine/Abacavir in HIV/Tuberculosis Co-Infected Patients Unknown status NCT01059422 Phase 4 Raltegravir; Abacavir/Lamivudine
21 MEDICLAS Study (Metabolic Effects of Different Classes of AntiretroviralS) Unknown status NCT00122226 Phase 4 Lopinavir/ritonavir + zidovudine + lamivudine;Lopinavir/ritonavir + nevirapine
22 Efavirenz to Dolutegravir Switch in Patients With CNS Toxicity Unknown status NCT02285374 Phase 4 Dolutegravir, efavirenz, efavirenz/emtricitabine/tenofovir
23 Maraviroc Abacavir STudy - Effect on Endothelial Recovery Unknown status NCT01389063 Phase 4 Maraviroc
24 Efficacy of PTX+IFN Alpha+ RBV on Hepatitis C Virus Coinfected HIV Patients Unknown status NCT02008214 Phase 4 Pentoxifylline;Placebo
25 Simplification From Protease Inhibitors to Raltegravir Unknown status NCT00941083 Phase 4 Raltegravir (Use RAL as a simplification strategy);Raltegravir (Use RAL as a simplification strategy);Raltegravir (Use RAL as a simplification strategy)
26 Safety and Efficacy Study Comparing Raltegravir to a Protease Inhibitor in Treatment-naïve, HIV/Hepatitis C Drug Users Unknown status NCT01105611 Phase 4 Raltegravir;Atazanavir/Ritonavir
27 Once Daily 3TC, Efavirenz and ddI for HIV Infection Unknown status NCT00214435 Phase 4 once daily minimum 3-drug regimen of anti-retroviral medications
28 Darunavir/Ritonavir + Lamivudine Versus Darunavir/Ritonavir +Emtricitabine/Tenofovir in Naïve HIV-1 Infected Subjects Completed NCT02770508 Phase 4 darunavir/ritonavir;Lamivudine;emtricitabine-tenofovir(FTC/TDF)
29 Evaluation of the Efficacy and Safety Between Two Antiretroviral Regimens, in HIV-1-infected Treatment-naïve Subjects With Low CD4 Counts Completed NCT01928407 Phase 4 DARUNAVIR;ATAZANAVIR
30 Evolution of Plasma Lipid Profile in Patients With HIV1 Who Change Atripla to Eviplera Compared to Continue With Atripla Completed NCT02547844 Phase 4 efavirenz + emtricitabina + tenofovir;rilpivirina + emtricitabina + tenofovir
31 Early Access to Low-dose Ritonavir (TMC114/r) and Other Antiretrovirals (ARVs) for Treatment-naive or Early Treatment Experienced in HIV-1 Patients Completed NCT01702090 Phase 4 TMC114/ritonavir
32 Valacyclovir vs. Acyclovir as HSV-2 Suppressive Therapy: Effect on Plasma HIV-1 Levels Among HIV-1/HSV-2 Co-infected Persons Completed NCT01026454 Phase 4 acyclovir;valacyclovir
33 BLQ Study: A Study of a Protease Inhibitor With Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With HIV-1. Completed NCT00326963 Phase 4 Background ARVs;PI;enfuvirtide [Fuzeon]
34 Atazanavir/Ritonavir, Once Daily + Raltegravir, Twice Daily, Switch Study in HIV-1—Infected Patients Completed NCT01332227 Phase 4 Atazanavir;Ritonavir (heat-stable);Raltegravir;Tenofovir/Emtricitabine
35 Peripheral Body Fat Distribution After Switching Zidovudine and Lamivudine to Truvada Completed NCT00324649 Phase 4 Truvada;Zidovudine/lamivudine
36 Compare the Efficacy and Safety of Raltegravir Versus Efavirenz Combination Therapy in Treatment-naïve HIV-1 Patients Completed NCT01989910 Phase 4 Raltegravir;Efavirenz
37 Safety and Efficacy Study of Switching From Epzicom to Truvada Completed NCT00724711 Phase 4 emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF);abacavir (ABC)/lamivudine (3TC)
38 HIV-1 Viral Dynamics in Subjects Initiating Raltegravir Therapy in Spain Completed NCT00685191 Phase 4 Salvage antiretroviral therapy including raltegravir
39 Tenofovir DF (Disoproxil Fumarate) in Combination With Emtricitabine in HIV-1 Patients Completed NCT00106379 Phase 4 Truvada (tenofovir DF + emtricitabine);Emtriva (emtricitabine);Viread (tenofovir DF)
40 A Simplification Study of Unboosted Reyataz With Epzicom (ASSURE) Completed NCT01102972 Phase 4 Reyataz + Norvir + Truvada;Reyataz + Epzicom
41 Study to Compare the Virologic Efficacy in Cerebrospinal Fluid (CSF) and Neurocognitive State in Patients Infected by HIV-1 Long-term Treatment (> 3 Years) With Lopinavir / Ritonavir Monotherapy Completed NCT01116817 Phase 4
42 Renal Effect of Stribild or Other Tenofovir DF-containing Regimens Compared to Ritonavir-boosted Atazanavir Plus Abacavir/Lamivudine in Antiretroviral Treatment-naive HIV-1 Infected Adults Completed NCT02246998 Phase 4 STB;TVD;ATR;RTV;ATV;ABC/3TC;Iohexol
43 Single Tablet Regimen (STR) Simplification Study for HIV-1 Infected Patients Completed NCT00365612 Phase 4 Efavirenz (EFV), Emtricitabine (FTC), Tenofovir DF (TDF)
44 Trial to Study the Effect of Dose of Herpes Simplex Virus-2 (HSV-2) Suppressive Therapy on HSV and HIV Completed NCT00527618 Phase 4 valacyclovir;acyclovir
45 ROCKET II - Randomized Open Label Switch for Cholesterol Elevation on Kivexa + Kaletra Evaluation Trial Completed NCT00772902 Phase 4 Truvada + Kaletra;Kivexa + Kaletra
46 Prospective Epidemiological Study Of The Prevalence Of HLAB*5701 In HIV-1 Infected Patients Completed NCT00441688 Phase 4 GI265235
47 Maraviroc in Immunological Non-Responder (INR) HIV-1-infected Subjects Completed NCT00884858 Phase 4 Maraviroc
48 Metabolic Effects of Atazanavir/Ritonavir Versus Darunavir/Ritonavir in Combination With Tenofovir/Emtricitabine in naïve HIV-1 Infected Patients Completed NCT01274780 Phase 4 Darunavir / Ritonavir + Tenofovir / Emtricitabine;Atazanavir / Ritonavir + Tenofovir / Emtricitabine
49 A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Etravirine Administered in Combination With Other Antiretroviral Agents in Antiretroviral Treatment-Experienced HIV-1 Infected Patients Completed NCT01422330 Phase 4 Etravirine
50 A5288/MULTI-OCTAVE: Management Using Latest Technologies to Optimize Combination Therapy After Viral Failure Completed NCT01641367 Phase 4 Darunavir;Etravirine;Emtricitabine/tenofovir disoproxil fumarate;Raltegravir;Second line ART regimens - based on a boosted protease inhibitor (bPI) plus two nucleoside analogues (NRTIs);Study provided drugs according to patient resistance profile (DRV, ETR, RTV, FTC/TDF) + any in country available drug as applicable & available

Search NIH Clinical Center for Human Immunodeficiency Virus Type 1

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Human Immunodeficiency Virus Type 1 cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Human Immunodeficiency Virus Type 1:
AGS-004, electroporated mature dendritic cells for HIV
Embryonic/Adult Cultured Cells Related to Human Immunodeficiency Virus Type 1:
Maturated and electroporated dendritic cells PMIDs: 20636001

Genetic Tests for Human Immunodeficiency Virus Type 1

Genetic tests related to Human Immunodeficiency Virus Type 1:

# Genetic test Affiliating Genes
1 Human Immunodeficiency Virus Type 1, Susceptibility to 30 CCL11 CCL2 CCL3 CCL3L1 CD209 CX3CR1 CXCL12 CXCR1 HLA-C IFNG IL10 IL4R KIR3DL1 TLR3

Anatomical Context for Human Immunodeficiency Virus Type 1

MalaCards organs/tissues related to Human Immunodeficiency Virus Type 1:

42
T Cells, Testes, Bone, Brain, Monocytes, Liver, Kidney

Publications for Human Immunodeficiency Virus Type 1

Articles related to Human Immunodeficiency Virus Type 1:

(show top 50) (show all 7405)
# Title Authors Year
1
Factors associated with the efficiency of hearing aids for patients with age-related hearing loss. ( 30880929 )
2019
2
A Randomized Controlled Trial Comparing Learners' Decision-making, Anxiety, and Task Load During a Simulated Airway Crisis Using Two Difficult Airway Aids. ( 30908420 )
2019
3
The impacts of depression and anxiety on quality of life among patients with HIV/AIDS and their spouses: testing dyadic dynamics using the actor-partner interdependence model. ( 30884955 )
2019
4
Atrial fibrillation and human immunodeficiency virus type-1 infection: a systematic review. Implications for anticoagulant and antiarrhythmic therapy. ( 30575989 )
2019
5
Adaptation and qualitative evaluation of encounter decision aids in breast cancer care. ( 30649604 )
2019
6
Feasibility and Efficacy of Decision Aids to Improve Decision Making for Postmastectomy Breast Reconstruction: A Systematic Review and Meta-analysis. ( 30799692 )
2019
7
Highly Active Antiretroviral Therapy and Gamma Knife Radiosurgery for the Treatment of AIDS-Related Primary Central Nervous System Lymphoma: A Case Report. ( 30654158 )
2019
8
Cisplatin and radiation therapy in HIV-positive women with locally advanced cervical cancer in sub-Saharan Africa: A phase II study of the AIDS malignancy consortium. ( 30773222 )
2019
9
Novel canine anti-Coccidioides immunoglobulin G enzyme immunoassay aids in diagnosis of coccidioidomycosis in dogs. ( 30649403 )
2019
10
Successful Management of Cryptococcal Meningitis and Bone Marrow Infiltration in a Young HIV/AIDS Patient: A Case Report and Review of the Literature. ( 30915244 )
2019
11
Making Homes More Dementia-Friendly through the Use of Aids and Adaptations. ( 30884814 )
2019
12
HIV/AIDS in the guise of a demyelinating disease. ( 30903790 )
2019
13
Predicting the Antiretroviral Medication Adherence and CD4 Measure in Patients with HIV/AIDS Based on the Post Traumatic Stress Disorder and Depression. ( 30847322 )
2019
14
Depression among Adult HIV/AIDS Patients Attending ART Clinics at Aksum Town, Aksum, Ethiopia: A Cross-Sectional Study. ( 30863637 )
2019
15
Factors associated with depression among HIV/AIDS children in China. ( 30828360 )
2019
16
Differential effects of unemployment on depression in people living with HIV/AIDS: a quantile regression approach. ( 30835499 )
2019
17
Correction: Gender disparities in depression severity and coping among people living with HIV/AIDS in Kolkata, India. ( 30794707 )
2019
18
Depression, social support, and stigma as predictors of quality of life over time: results from an Asha-based HIV/AIDS intervention in India. ( 30714386 )
2019
19
Decision aids for people with Type 2 diabetes mellitus: an effectiveness rapid review and meta-analysis. ( 30791131 )
2019
20
Teamwork aids management and raises new issues in epilepsy. ( 30617307 )
2019
21
Progressive disseminated histoplasmosis with concomitant disseminated nontuberculous mycobacterial infection in a patient with AIDS from a nonendemic region (California). ( 30791902 )
2019
22
Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted Human Immunodeficiency Virus Type 1 Drug Resistance in a Large US Clinic Population. ( 29846534 )
2019
23
Pretreatment human immunodeficiency virus type 1 (HIV-1) drug resistance in transmission clusters of the Cologne-Bonn region, Germany. ( 30315957 )
2019
24
Performance of Geno2Pheno[coreceptor] to infer coreceptor use in human immunodeficiency virus type 1 (HIV-1) subtype A. ( 30594700 )
2019
25
Osteopontin counters human immunodeficiency virus type 1-induced impairment of neurite growth through mammalian target of rapamycin and beta-integrin signaling pathways. ( 30758811 )
2019
26
Gold nanoparticle-carboxymethyl cellulose nanocolloids for detection of human immunodeficiency virus type-1 (HIV-1) using laser light scattering immunoassay. ( 30785035 )
2019
27
Detection of antisense protein (ASP) RNA transcripts in individuals infected with human immunodeficiency virus type 1 (HIV-1). ( 30896385 )
2019
28
AIDS-Related Kaposi Sarcoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. ( 30787130 )
2019
29
Lung Cancer Screening Benefits and Harms Stratified by Patient Risk: Information to Improve Patient Decision Aids. ( 30620619 )
2019
30
Activity of brentuximab vedotin in AIDS-related primary effusion lymphoma. ( 30837213 )
2019
31
Fatal measles as AIDS presentation in Italy. ( 30672113 )
2019
32
Melanoma-induced reprogramming of Schwann cell signaling aids tumor growth. ( 30914431 )
2019
33
Merkel Cell Carcinoma in the HIV-1/AIDS Patient. ( 30523626 )
2019
34
Contributions of traditional and HIV-related risk factors on non-AIDS-defining cancer, myocardial infarction, and end-stage liver and renal diseases in adults with HIV in the USA and Canada: a collaboration of cohort studies. ( 30683625 )
2019
35
Different walk aids on gait parameters and kinematic analysis of the pelvis in patients with Adult Neuromuscular Disease. ( 30842398 )
2019
36
Auditory Neuropathy: Bridging the Gap Between Hearing Aids and Cochlear Implants. ( 30765091 )
2019
37
Pilot Study Examining Feasibility and Comparing the Effectiveness of Decision Aids for Hip and Knee Osteoarthritis: A Randomized Trial. ( 30801033 )
2019
38
Clinical and microbiological characteristics of paracoccidioidomycosis in patients with AIDS in Buenos Aires, Argentina. ( 30874811 )
2019
39
A Model to Predict In-Hospital Mortality in HIV/AIDS Patients with Pneumocystis Pneumonia in China: The Clinical Practice in Real World. ( 30906778 )
2019
40
Case of coincident severe acne and psoriasis in AIDS patient successfully treated with antiretroviral therapy. ( 30811070 )
2019
41
Kaposi's Sarcoma-Associated Herpesvirus (KSHV)-Associated Disease in the AIDS Patient: An Update. ( 30523621 )
2019
42
Circulating miRNA-375 as a potential novel biomarker for active Kaposi's sarcoma in AIDS patients. ( 30549196 )
2019
43
A Longitudinal Analysis of the Substance Abuse, Violence, and HIV/AIDS (SAVA) Syndemic among Women in the Criminal Justice System. ( 30626264 )
2019
44
IMPLICATION OF FIVE AIDS RELATED GENES IN MOTHER-TO-CHILD TRANSMISSION AND ACQUISITION OF HUMAN IMMUNODEFICIENCY VIRUS 1 IN CAMEROON. ( 30596191 )
2019
45
Executive summary of the GeSIDA/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2018). ( 29759422 )
2019
46
Mixed infection by Histoplasma capsulatum isolates with different mating types in Brazilian AIDS-patients. ( 30785562 )
2019
47
Emergence of antibiotic resistance in immunocompromised host populations: A case study of emerging antibiotic resistant tuberculosis in AIDS patients. ( 30817798 )
2019
48
Anthony Fauci: fighting HIV/AIDS from the beginning. ( 30910295 )
2019
49
Naturopathy and Yoga as an Adjuvant for People Living With HIV/AIDS - A Case Series Report. ( 30910609 )
2019
50
Improving the Youth HIV Prevention and Care Continuums: The Adolescent Medicine Trials Network for HIV/AIDS Interventions. ( 30912750 )
2019

Variations for Human Immunodeficiency Virus Type 1

ClinVar genetic disease variations for Human Immunodeficiency Virus Type 1:

6 (show all 22)
# Gene Variation Type Significance SNP ID Assembly Location
1 CD209 CD209, -336A-G single nucleotide variant protective,risk factor
2 CCR5 NM_000579.3(CCR5): c.554_585del32 (p.Ser185Ilefs) deletion protective,risk factor rs333 GRCh37 Chromosome 3, 46414947: 46414978
3 CCR5 NM_000579.3(CCR5): c.554_585del32 (p.Ser185Ilefs) deletion protective,risk factor rs333 GRCh38 Chromosome 3, 46373456: 46373487
4 CCR5 NM_000579.3(CCR5): c.303T> A (p.Cys101Ter) single nucleotide variant protective rs1800560 GRCh37 Chromosome 3, 46414696: 46414696
5 CCR5 NM_000579.3(CCR5): c.303T> A (p.Cys101Ter) single nucleotide variant protective rs1800560 GRCh38 Chromosome 3, 46373205: 46373205
6 CCR5 NM_000579.3(CCR5): c.-301+246A> G single nucleotide variant protective rs1799987 GRCh37 Chromosome 3, 46411935: 46411935
7 CCR5 NM_000579.3(CCR5): c.-301+246A> G single nucleotide variant protective rs1799987 GRCh38 Chromosome 3, 46370444: 46370444
8 CCR5 NM_000579.3(CCR5): c.180G> T (p.Arg60Ser) single nucleotide variant protective rs1800940 GRCh37 Chromosome 3, 46414573: 46414573
9 CCR5 NM_000579.3(CCR5): c.180G> T (p.Arg60Ser) single nucleotide variant protective rs1800940 GRCh38 Chromosome 3, 46373082: 46373082
10 CCR2 NM_001123041.2(CCR2): c.190G> A (p.Val64Ile) single nucleotide variant protective rs1799864 GRCh37 Chromosome 3, 46399208: 46399208
11 CCR2 NM_001123041.2(CCR2): c.190G> A (p.Val64Ile) single nucleotide variant protective rs1799864 GRCh38 Chromosome 3, 46357717: 46357717
12 CCL11 CCL11, -1385G-A single nucleotide variant protective
13 CXCL12 NM_000609.6(CXCL12): c.266+535G> A single nucleotide variant protective rs387906400 GRCh37 Chromosome 10, 44873550: 44873550
14 CXCL12 NM_000609.6(CXCL12): c.266+535G> A single nucleotide variant protective rs387906400 GRCh38 Chromosome 10, 44378102: 44378102
15 CCL2 CCL2, -2136A-T single nucleotide variant protective
16 CCL2 CCL2, 767C-G single nucleotide variant protective
17 HLA-C NC_000006.12: g.31306603T> C single nucleotide variant risk factor rs9264942 GRCh38 Chromosome 6, 31306603: 31306603
18 HLA-C NC_000006.12: g.31306603T> C single nucleotide variant risk factor rs9264942 GRCh37 Chromosome 6, 31274380: 31274380
19 IL10 NM_000572.3(IL10): c.-627A> C single nucleotide variant protective,risk factor rs1800872 GRCh38 Chromosome 1, 206773062: 206773062
20 IL10 NM_000572.3(IL10): c.-627A> C single nucleotide variant protective,risk factor rs1800872 GRCh37 Chromosome 1, 206946407: 206946407
21 TLR3 NM_003265.2(TLR3): c.1234C> T (p.Leu412Phe) single nucleotide variant protective rs3775291 GRCh37 Chromosome 4, 187004074: 187004074
22 TLR3 NM_003265.2(TLR3): c.1234C> T (p.Leu412Phe) single nucleotide variant protective rs3775291 GRCh38 Chromosome 4, 186082920: 186082920

Copy number variations for Human Immunodeficiency Virus Type 1 from CNVD:

7 (show all 23)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13736 1 1 247249719 Copy number HIV/AIDS
2 74031 13 1 114142980 Copy number HIV/AIDS
3 107129 17 1225928 31649829 Copy number CCL3L3 HIV/AIDS
4 107135 17 1225928 31649843 Copy number CCL3L1 HIV/AIDS
5 107136 17 1225928 31649843 Copy number CCL3L1 HIV/AIDS
6 107137 17 1225928 31649843 Copy number CCL3L1 HIV/AIDS
7 107145 17 1225928 31649843 Segmental duplicatio ns CCL3L1 HIV/AIDS
8 107159 17 1242109 31665953 Copy number CCL4L2 HIV/AIDS
9 110228 17 31562580 31665959 Copy number CCL4L1 HIV/AIDS
10 110279 17 31800000 38100000 Copy number CCL3L1 HIV/AIDS
11 110285 17 31800000 38100000 Copy number CCL4L1 HIV/AIDS
12 110286 17 31800000 38100000 Copy number CCL4L1 HIV/AIDS
13 110848 17 34522267 34625730 Copy number CCL3L1 HIV/AIDS
14 111275 17 35400000 35600000 Copy number CCL3L1 HIV/AIDS
15 112166 17 38100000 38400000 Copy number CCL3L1 HIV/AIDS
16 112167 17 38100000 38400000 Copy number CCL3L1 HIV/AIDS
17 112170 17 38100000 38400000 Loss CCL3L1 HIV/AIDS
18 179925 4 1 191273063 Copy number HIV/AIDS
19 209403 6 2614953 31491069 Copy number MICA HIV/AIDS
20 211349 6 32593131 32665540 Copy number HLA-DRB5 HIV/AIDS
21 212276 6 3674895 32665540 Copy number HLA-DRB1 HIV/AIDS
22 212425 6 3795995 32719407 Copy number HLA-DQA1 HIV/AIDS
23 212441 6 3813334 32742444 Copy number HLA-DQB1 HIV/AIDS

Expression for Human Immunodeficiency Virus Type 1

Search GEO for disease gene expression data for Human Immunodeficiency Virus Type 1.

Pathways for Human Immunodeficiency Virus Type 1

Pathways related to Human Immunodeficiency Virus Type 1 according to GeneCards Suite gene sharing:

(show all 38)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.96 BST2 CCL11 CCL2 CCL3 CCL3L1 CCR2
2
Show member pathways
13.83 CCL11 CCL2 CCL3 CCL3L1 CCR2 CCR5
3
Show member pathways
13.66 CCL11 CCL2 CCL3 CCL3L1 CCR2 CCR5
4
Show member pathways
13.5 CCL11 CCL2 CCL3 CCL3L1 CXCL12 IFNG
5
Show member pathways
13.37 CCL11 CCL2 CCL3 CCL3L1 CCR2 CCR5
6
Show member pathways
13.31 BST2 CCL11 CCL2 CCL3 CCL3L1 CCR2
7
Show member pathways
13.17 CCL11 CCL2 CCL3 CCL3L1 CCR2 CCR5
8
Show member pathways
13.15 CCL2 CCL3 CCL3L1 IFNG IL10 TLR3
9
Show member pathways
13.08 CCL11 CCL2 CCL3 CCL3L1 CCR2 CCR5
10
Show member pathways
12.95 BST2 CCL2 CCL3 CCL3L1 CCR5 CXCL12
11
Show member pathways
12.88 CCL11 CXCL12 HLA-C IFNG IL10 IL4R
12
Show member pathways
12.73 CCL11 CCL2 CCL3 CCL3L1 CCR2 CCR5
13 12.57 CCL2 CCR2 CXCL12 IFNG IL10 TLR3
14
Show member pathways
12.54 CCL2 CD209 HLA-C IFNG TLR3
15
Show member pathways
12.41 CCR2 CCR5 CXCL12 IFNG IL10 IL4R
16
Show member pathways
12.25 BST2 CXCL12 HLA-C IFNG IL10
17
Show member pathways
12.02 CCL11 CCL2 CCL3 CCL3L1 CXCL12 IFNG
18
Show member pathways
12.01 CCL11 CCL2 CCL3 CCL3L1 CCR2 CCR5
19 11.98 CD209 CX3CR1 IFNG IL10
20 11.96 CCL11 CCL2 IL10 IL4R
21
Show member pathways
11.9 CCL3 CCR5 IFNG
22 11.88 CCL2 CCL3 CCL3L1 CXCL12 IFNG
23 11.85 CCR2 CCR5 CXCL12 IFNG IL10 IL4R
24 11.78 CCL3 CCL3L1 IFNG
25 11.77 CD209 CX3CR1 IFNG IL10
26 11.74